Monitoring Pathological Response in Breast Cancer Patients Using AI
Author Information
Author(s): Maria Colomba Comes, Annarita Fanizzi, Samantha Bove, Luca Boldrini, Agnese Latorre, Deniz Can Guven, Serena Iacovelli, Tiziana Talienti, Alessandro Rizzo, Francesco Alfredo Zito, Raffaella Massafra
Primary Institution: I.R.C.C.S. Istituto Tumori “Giovanni Paolo II” Bari Italy
Hypothesis
Can an ensemble deep learning model using Vision Transformers predict and monitor pathological complete response to neoadjuvant chemotherapy in breast cancer patients?
Conclusion
Changes in DCE-MRI at pre- and mid-treatment could affect the accuracy of predicting pathological complete response to neoadjuvant chemotherapy.
Supporting Evidence
- The model achieved an AUC of 91.4% on the internal test set.
- Accuracy was 82.4%, with a sensitivity of 85.7% and specificity of 80.0%.
- 37.2% of patients in the study achieved pathological complete response.
Takeaway
Doctors can use special computer models to see how well breast cancer treatment is working by looking at pictures of the tumors before and during treatment.
Methodology
The study used DCE-MRI scans from 86 breast cancer patients and developed a deep learning model to predict pCR based on imaging data.
Potential Biases
The study may be limited by the specific characteristics of the patient population and imaging techniques used.
Limitations
The model's performance varied between the internal cohort and the independent test set, indicating potential context-dependency.
Participant Demographics
The cohort included 86 breast cancer patients, with 37.2% achieving pathological complete response.
Statistical Information
P-Value
0.0045
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website